(e,e,e,e)-squalene is a lipid of Fatty Acyls (FA) class. (e,e,e,e)-squalene is associated with abnormalities such as Hypercholesterolemia and Cataract. The involved functions are known as Process, metaplastic cell transformation, Protein Overexpression, Anabolism and Biosynthetic Pathways. (e,e,e,e)-squalene often locates in Membrane, Protoplasm, Plasma membrane, Tissue membrane and Back. The associated genes with (e,e,e,e)-squalene are Genome, IMPACT gene, GAPDH gene, GTF2I gene and Chromatin. The related lipids are Membrane Lipids, cycloartenol, Sterols, Fatty Acids and Nonesterified Fatty Acids.
To understand associated biological information of (e,e,e,e)-squalene, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
(e,e,e,e)-squalene is suspected in Hypercholesterolemia, Cataract and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with (e,e,e,e)-squalene
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Higgins DA et al. | MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice. | 1996 | Vaccine | pmid:8782343 |
Hilgers LA et al. | Sulfolipo-cyclodextrin in squalane-in-water as a novel and safe vaccine adjuvant. | 1999 | Vaccine | pmid:9987157 |
Madhun AS et al. | An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers. | 2010 | Vaccine | pmid:21034828 |
Garcia-Sicilia J et al. | Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents. | 2011 | Vaccine | pmid:21504774 |
Camilloni B et al. | Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages. | 2009 | Vaccine | pmid:19410623 |
Fabbiani M et al. | Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients. | 2011 | Vaccine | pmid:21349364 |
O'Hagan DT et al. | Cationic microparticles are a potent delivery system for a HCV DNA vaccine. | 2004 | Vaccine | pmid:15542189 |
Chandramouli S et al. | Generation of a parvovirus B19 vaccine candidate. | 2013 | Vaccine | pmid:23827313 |
Yang WH et al. | Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trial. | 2013 | Vaccine | pmid:23856331 |
Rouleau I et al. | Increased risk of anaphylaxis following administration of 2009 AS03-adjuvanted monovalent pandemic A/H1N1 (H1N1pdm09) vaccine. | 2013 | Vaccine | pmid:24144473 |